Kidney damage in patients with inflammatory bowel diseases: a clinical case

DOI: https://doi.org/10.29296/25877305-2023-10-10
Issue: 
10
Year: 
2023

Associate Professor V. Poliakova, Candidate of Medical Sciences; Professor
N. Kunitskaya, MD; A. Сhistyakova; N. Bakulina
I.I. Mechnikov North-West State Medical University, Ministry of Health of Russia, Saint Petersburg

Kidney damage in patients with inflammatory bowel diseases often presents difficulties for early diagnosis and management of such patients, which is largely due to the absence of pronounced clinical manifestations, at the same time there is a fairly short time interval for reversibility of renal damage, which requires a certain alertness of practitioners. This article presents a clinical case of a 32-year-old patient with a long history of systemic inflammatory disease who consulted a nephrologist due to increasing azotemia.
Keywords: 
gastroenterology
nephrology
inflammatory bowel disease; ulcerative colitis
Crohn's disease
kidney disease; glomerular kidney disease
tubulointerstitial nephritis. granulomatosis.

References: 
  1. Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005; 11 (46): 7227–36. DOI: 10.3748/wjg.v11.i46.7227
  2. Corica D., Romano C. Renal Involvement in Inflammatory Bowel Diseases. J Crohns Colitis. 2016; 10 (2): 226–35. DOI: 10.1093/ecco-jcc/jjv138
  3. Rogler G., Singh A., Kavanaugh A. et al. Extraintestinal Manifestations of inflammatory Bowel disease: current concepts? Treatment, and implications for disease management. Gastroenterology. 2021; 161 (4): 1118–32. DOI: 10.1053/j.gastro.2021.07.042
  4. Malik T.F., Aurelio D.M. Extraintestinal Manifestations of Inflammatory Bowel Disease, In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022, 2021.
  5. Егоров Д.В., Лазарева Ю.А., Иванюк Е.С. и др. Особенности ректального лечения воспалительных заболеваний кишечника. Лечащий Врач. 2023; 6: 69–76 [Egorov D.V., Lazareva Yu.A., Ivanyuk E.S. et al. Features of rectal treatment of inflammatory bowel diseases. Lechaschi Vrach. 2023; 6: 69–77 (in Russ.)]. DOI: 10.51793/OS.2023.26.6.010
  6. Ambruzs J.M., Larsen C.P. Renal Manifestations of Inflammatory Bowel Disease. Rheum Dis Clin North Am. 2018; 44 (4): 699–714. DOI: 10.1016/j.rdc.2018.06.007
  7. Vavricka S.R., Schoepfer A., Scharl M. et al. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015; 21 (8): 1982–92. DOI: 10.1097/MIB.0000000000000392
  8. Ambruzs J.M., Walker P.D., Larsen C.P. The Histopathologic Spectrum of Kidney Biopsies in Patients with Inflammatory Bowel Disease. Clin J Am Soc Nephrol. 2014; 9 (2): 265–70. DOI: 10.2215/CJN.04660513
  9. Co M.L., Gorospe E.C. Pediatric case of mesalazine-induced interstitial nephritis with literature review. Pediatr Int. 2013; 55 (3): 385–7. DOI: 10.1111/j.1442-200X.2012.03745.x
  10. Gisbert J.P., Gonzalez-Lama Y., Mate J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007; 13 (5): 629–38. DOI: 10.1002/ibd.20099
  11. Elseviers M.M., D’Haens G., Lerebours E. et al. Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy? Clin Nephrol. 2004; 61 (2): 83–9. DOI: 10.5414/cnp61083
  12. Treffel M., Champigneulle J., Meibody F. et al. Tubulointerstitiel nephritis and Crohn's disease, nephrotoxicity or extraintestinal manifestation of Crohn's disease? About a case. Nephrol Ther. 2019; 15 (1): 59–62. DOI: 10.1016/j.nephro.2018.07.406
  13. Laass M.W., Roggenbuck D., Conrad K. Diagnosis and classification of Crohn’s disease. Autoimmun Rev. 2014; 13 (4-5): 467–71. DOI: 10.1016/j.autrev.2014.01.029
  14. Waters A.M., Zachos M., Herzenberg A.M. et al. Tubulointerstitial nephritis as an extraintestinal manifestation of Crohn’s disease. Nat Clin Pract Nephrol. 2008; 4 (12): 693–7. DOI: 10.1038/ncpneph0955
  15. Elaziz M.M.A., Fayed A. Patterns of renal involvement in a cohort of patients with inflammatory bowel disease in Egypt. Acta Gastroenterol Belg. 2018; 81 (3): 381–5.
  16. Takemura T., Okada M., Yagi K. et al. An adolescent with IgA nephropathy and Crohn disease: pathogenetic implications. Pediatr Nephrol. 2002; 17 (10): 863–6. DOI: 10.1007/s00467-002-0943-x
  17. Forshaw M.J., Guirguis O., Hennigan T.W. IgA nephropathy in association with Crohn’s disease. Int J Colorectal Dis. 2005; 20 (5): 463–5. DOI: 10.1007/s00384-004-0696-z
  18. Filiopoulos V., Trompouki S., Hadjiyannakos D. et al. IgA nephropathy in association with Crohn’s disease: A case report and brief review of the literature. Ren Fail. 2010; 32 (4): 523–7. DOI: 10.3109/08860221003710554
  19. Ku E., Ananthapanyasut W., Campese V.M. IgA nephropathy in a patient with ulcerative colitis, Graves’ disease and positive myeloperoxidase ANCA. Clin Nephrol. 2012; 77 (2): 146–50. DOI: 10.5414/CN106770
  20. Choi J.Y., Yu C.H., Jung H.Y. et al. A case of rapidly progressive IgA nephropathy in a patient with exacerbation of Crohn’s disease. BMC Nephrol. 2012; 13: 84. DOI: 10.1186/1471-2369-13-84
  21. Kiryluk K., Li Y., Scolari F. et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014; 46 (11): 1187–96. DOI: 10.1038/ng.3118
  22. Wester A.L., Vatn M.H., Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis. 2001; 7 (4): 295–30. DOI: 10.1097/00054725-200111000-00003
  23. Tosca Cuquerella J., Bosca-Watts M.M., Anton Ausejo R. et al. Amyloidosis in inflammatory bowel disease: a systematic review of epidemiology, clinical features, and treatment. J Crohns Colitis. 2016; 10 (10): 1245–53. DOI: 10.1093/ecco-jcc/jjw080
  24. Pukitis A., Zake T., Groma V. et al. Effect of infliximab induction n therapy on secondary systemic amyloidosis associated with Crohn’s disease: case report and review of the literature. J Gastrointestin Liver Dis. 2013; 22 (3): 333–6.
  25. Sy A., Khalidi N., Dehghan N. et al. Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. Semin Arthritis Rheum. 2016; 45 (4): 475–82. DOI: 10.1016/j.semarthrit.2015.07.006
  26. McConnell N., Campbell S., Gillanders I. et al. Risk factors for developing renal stones in inflammatory bowel disease. BJU Int. 2002; 89 (9): 835–41. DOI: 10.1046/j.1464-410x.2002.02739.x
  27. Hueppelshaeuser R., von Unruh G.E., Habbig S. et al. Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn’s disease. Pediatr Nephrol. 2012; 27 (7): 1103–9. DOI: 10.1007/s00467-012-2126-8
  28. Salem A.,·Sawires H., Eskander A. et al. Risk factors for developing hyperoxaluria in children with Crohn’s disease. Pediatr Nephrol. 2023; 38 (3): 781–9. DOI: 10.1007/s00467-022-05674-3
  29. Lumlertgul N., Siribamrungwong M., Jaber B.L. et al. Secondary oxalate nephropathy: a systematic review. Kidney Int Rep. 2018; 3 (6): 1363–72. DOI: 10.1016/j.ekir.2018.07.020
  30. Buysschaert B., Aydin S., Morelle J. et al. Etiologies, clinical features, and outcome of oxalate nephropathy. Kidney Int Rep. 2020; 5 (9): 1503–9. DOI: 10.1016/j.ekir.2020.06.021
  31. Yang Y., Sharma P.D., Nair V. et al. Kidney oxalate crystal deposition in adult patients: a relatively common finding. Clin Nephrol. 2020; 93 (5): 243–50. DOI: 10.5414/CN109980
  32. Cury D.B., Moss A.C., Schor N. Nephrolithiasis in patients with inflammatory bowel disease in the community. Int J Nephrol Renovasc Dis. 2013; 6: 139–42. DOI: 10.2147/IJNRD.S45466
  33. Kreisel W., Wolf L.M., Grotz W. et al. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1996; 8 (5): 461–8.
  34. Rosenstock J.L., Joab T.M.J., DeVita M.V. et al. Oxalate nephropathy: a review. Clin Kidney J. 2022; 15 (2): 194–204. DOI: 10.1093/ckj/sfab145